```html

Zollinger‑Ellison Syndrome (Gastrinoma) – A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (called gastrinomas) develop in the pancreas, duodenum, or nearby tissues. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach to produce large volumes of acid. The resulting hyperacidity can lead to severe peptic ulcers and a host of gastrointestinal symptoms.

Who is affected? ZES can occur at any age but most commonly appears in adults between 30 and 60 years old. There is a slight male predominance (about 55 % male) and a higher incidence among people of Asian descent, although cases are reported worldwide.

Prevalence: Gastrinomas are the most common functional neuroendocrine tumors of the pancreas, with an estimated incidence of 0.5–2 cases per million people per year (Mayo Clinic, 2023). Approximately 20–30 % of patients with gastrinomas have ZES as part of the hereditary multiple endocrine neoplasia type 1 (MEN‑1) syndrome (NIH, 2022).

Symptoms

Because excess gastric acid affects many parts of the digestive tract, ZES produces a wide range of symptoms. The severity often correlates with tumor size and the amount of gastrin secreted.

Gastro‑intestinal manifestations

• Refractory peptic ulcers – multiple ulcers in the duodenum, jejunum, or even the distal ileum; they rarely heal with standard therapy.
• Abdominal pain – usually epigastric, described as burning or gnawing; pain may worsen after meals.
• Diarrhea – secretory diarrhea caused by acid inactivation of pancreatic enzymes and injury to intestinal mucosa.
• Gastro‑esophageal reflux disease (GERD) – acid overload can lead to persistent heartburn.
• Nausea & vomiting – especially after large meals.
• Weight loss – due to malabsorption and chronic diarrhea.

Extra‑intestinal signs

• Fatigue and anemia – chronic blood loss from ulcers.
• Steatorrhea (fatty stools) – impaired fat digestion from pancreatic enzyme inactivation.
• Osteoporosis – long‑term acid hypersecretion can reduce calcium absorption.
• Skin flushing or itching – occasional in patients with MEN‑1.

Note: Symptoms may be subtle for months, leading to delayed diagnosis. Any patient with recurrent or treatment‑resistant ulcers should be evaluated for ZES.

Causes and Risk Factors

ZES is primarily caused by gastrin‑producing neuroendocrine tumors (gastrinomas). The etiology can be divided into sporadic and hereditary forms.

1. Sporadic gastrinomas

• Arise de novo in the pancreas (≈60 %) or duodenum (≈30 %).
• Most are malignant (≈70 %) and can metastasize to the liver or lymph nodes.

2. Hereditary MEN‑1 syndrome

• Autosomal‑dominant mutation in the MEN1 tumor suppressor gene.
• Patients develop multiple endocrine tumors (parathyroid, pituitary, pancreatic). About 20–30 % of MEN‑1 patients develop gastrinomas.

Risk factors

• Family history of MEN‑1 or known MEN1 gene mutation.
• Previous history of pancreatic neuroendocrine tumors.
• Age >30 years (most cases diagnosed after this age).
• Male sex (slight increase).

Diagnosis

Because symptoms overlap with common ulcer disease, a systematic approach is essential.

1. Biochemical testing

• Fasting serum gastrin level – a level > 1000 pg/mL (normal < 100 pg/mL) strongly suggests ZES. However, levels > 200 pg/mL together with a gastric pH < 2 are diagnostic (Mayo Clinic, 2023).
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is highly specific for gastrinoma.
• Serum chromogranin A (CgA) – often elevated in neuroendocrine tumors, useful for monitoring.

2. Imaging studies

• Upper endoscopy (EGD) – identifies ulcer location, size, and may allow biopsy of surrounding mucosa.
• Contrast‑enhanced CT or MRI – first‑line for locating primary tumor and metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – the most sensitive method for detecting small gastrinomas (< 1 cm) and metastatic disease.
• EUS (endoscopic ultrasound) – excellent for duodenal lesions and for fine‑needle aspiration biopsy.

3. Histopathology

If a lesion is biopsied, pathology will show uniform neuroendocrine cells positive for gastrin, chromogranin A, and synaptophysin. Ki‑67 index helps grade tumor aggressiveness.

4. Genetic testing

Patients with a personal or family history suggestive of MEN‑1 should undergo germline MEN1 mutation analysis (NIH, 2022).

Treatment Options

Therapy is aimed at two goals: control of gastric acid secretion and removal or control of the tumor. A multidisciplinary team—gastroenterology, endocrinology, surgery, oncology, and nutrition—is ideal.

1. Acid‑suppression therapy (first line)

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are usually required. Doses may be 2–4 times the standard ulcer dose, taken twice daily.
• H2‑receptor antagonists – can be added if PPIs alone do not control symptoms, though PPIs are more effective.
• Goal: maintain gastric pH > 4 to allow ulcer healing and relieve diarrhea.

2. Surgical management

• Curative resection – indicated for solitary, non‑metastatic gastrinomas. Enucleation or pancreaticoduodenectomy (Whipple) may be performed depending on size/location.
• Debulking surgery – for metastatic disease; removes > 90 % of tumor burden to reduce gastrin output.
• Minimally invasive (laparoscopic/robotic) approaches are increasingly used for small duodenal lesions.

3. Medical therapy for tumor control

• Somatostatin analogues (octreotide, lanreotide) – bind to somatostatin receptors, inhibiting gastrin release and shrinking somatostatin‑receptor‑positive tumors.
• Targeted therapy – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for progressive pancreatic neuroendocrine tumors.
• Chemotherapy – limited role; reserved for high‑grade (G3) neuroendocrine carcinomas.
• Peptide receptor radionuclide therapy (PRRT) – Lu‑177‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; effective for metastatic disease.

4. Lifestyle and supportive measures

• Low‑acid diet (avoid caffeine, alcohol, spicy foods, citrus).
• Small, frequent meals to reduce gastric workload.
• Calcium and vitamin D supplementation if bone density is compromised.
• Vaccination against hepatitis B & C if liver metastases are present and treatment may affect liver function.

Living with Zollinger‑Ellison Syndrome (Gastrinoma)

Long‑term management focuses on symptom control, monitoring for recurrence, and maintaining overall health.

Daily Management Tips

• Medication adherence – take PPIs exactly as prescribed; never skip doses.
• Follow‑up labs – check fasting gastrin levels, CgA, and electrolytes every 3–6 months.
• Endoscopic surveillance – repeat EGD every 1–2 years to assess ulcer healing.
• Imaging schedule – cross‑sectional imaging or Ga‑68 DOTATATE PET/CT annually for metastatic disease.
• Nutrition – work with a dietitian to ensure adequate protein, calories, and fat intake; consider pancreatic enzyme replacement if steatorrhea persists.
• Bone health – DEXA scan every 2–3 years; supplement with calcium 1,200 mg/day and vitamin D 800–1,000 IU/day unless contraindicated.
• Psychosocial support – chronic disease can affect mood; counseling or support groups (e.g., NET Patient Foundation) can be valuable.

Travel & Lifestyle

• Carry a short‑acting antacid (e.g., calcium carbonate) for breakthrough symptoms.
• Keep a list of your medications, doses, and the name of your specialty center in case of emergencies abroad.
• Stay hydrated; chronic diarrhea can lead to electrolyte loss.

Prevention

Because ZES is driven by tumor formation, true primary prevention is limited. However, certain strategies may lower risk or aid early detection:

• Genetic counseling for families with MEN‑1; early screening (annual fasting gastrin, imaging) can identify gastrinomas before symptoms develop.
• Avoid chronic gastric irritants such as long‑term NSAIDs, which may mask ulcer symptoms and delay diagnosis.
• Regular medical check‑ups for patients with known pancreatic neuroendocrine tumors or other MEN‑1 manifestations.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Perforated ulcer – life‑threatening intra‑abdominal infection.
• Gastrointestinal bleeding – may require transfusion or endoscopic therapy.
• Severe malabsorption – leading to protein‑energy wasting, anemia, and electrolyte disturbances.
• Metastatic disease – liver, lymph nodes, or bones; can cause hepatic failure or bone pain.
• Osteoporosis & fractures – chronic acid exposure impairs calcium absorption.
• Secondary infections – due to chronic PPI use (e.g., C. difficile).

When to Seek Emergency Care

References

• Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
• National Institutes of Health (NIH). “Multiple Endocrine Neoplasia Type 1.” 2022. https://www.nih.gov
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome) Treatment.” 2023. https://my.clevelandclinic.org
• World Health Organization (WHO). “Neuroendocrine Tumors – Classification.” 2021. https://www.who.int
• American Society for Gastrointestinal Endoscopy (ASGE). “Guidelines for Diagnosis and Management of Zollinger‑Ellison Syndrome.” 2022.
• Jonklaas J, et al. “Somatostatin analogues in the management of gastrinomas.” *Journal of Clinical Endocrinology & Metabolism*, 2020.

```